Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
GlobalRPh RX List - BARACLUDE
Product / population
Adult entecavir: retain the usual 0.5 mg column versus the 1 mg column for lamivudine-refractory infection or decompensated liver disease.
Renal method
Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-08
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
BARACLUDE: the usual regimen selects the renal-table column
The 0.5 mg and 1 mg columns represent different clinical contexts. The source favors daily schedules and uses solution for small doses.
What to reconcile: Establish treatment history/liver status, then select the corresponding complete renal schedule and formulation. Do not mix the two columns.
GlobalRPh-hosted RX List · Adult entecavir: retain the usual 0.5 mg column versus the 1 mg column for lamivudine-refractory infection or decompensated liver disease.
Renal method: Estimated creatinine clearance (CrCl), mL/min. The selected subsection does not independently establish an estimating equation. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-08
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Adult source table; once-daily regimens are preferred:
CrCl (mL/min)
Usual 0.5 mg regimen
Usual 1 mg regimen
>=50
0.5 mg daily
1 mg daily
30 to <50
0.25 mg daily OR 0.5 mg every 48 hours
0.5 mg daily OR 1 mg every 48 hours
10 to <30
0.15 mg daily OR 0.5 mg every 72 hours
0.3 mg daily OR 1 mg every 72 hours
<10, HD or CAPD
0.05 mg daily OR 0.5 mg every 7 days
0.1 mg daily OR 1 mg every 7 days
Use oral solution for doses below 0.5 mg. Give after hemodialysis on dialysis days. Do not select a column from renal function alone.
RDM45-rxlist-entecavir-18f643a4b3-C1 · Source locator: Dosage and Administration: Table 2 and footnotes, lines 66-84.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.